New hope for Tough-to-Treat colon cancer
NCT ID NCT07229846
Summary
This study is testing whether adding a new immunotherapy drug (aipalolitovorelizumab) to standard chemotherapy and another targeted drug (bevacizumab) works better for people with advanced colorectal cancer that has spread and has a specific genetic change called BRAF V600E. The trial will enroll 30 adults who haven't had prior treatment for their metastatic cancer. Researchers will measure how well tumors shrink and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hosptital
Harbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.